| Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis D Hodgson, R Pebody, J Panovska-Griffiths, M Baguelin, KE Atkins BMC medicine 18, 1-14, 2020 | 63 | 2020 |
| Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis D Hodgson, M Baguelin, E van Leeuwen, J Panovska-Griffiths, M Ramsay, ... The lancet Public health 2 (2), e74-e81, 2017 | 59 | 2017 |
| Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study Y Li, D Hodgson, X Wang, KE Atkins, DR Feikin, H Nair The Lancet Infectious Diseases 21 (9), 1303-1312, 2021 | 49 | 2021 |
| The potential for vaccination-induced herd immunity against the SARS-CoV-2 B. 1.1. 7 variant D Hodgson, S Flasche, M Jit, AJ Kucharski, ... Eurosurveillance 26 (20), 2100428, 2021 | 43 | 2021 |
| Determinants of RSV epidemiology following suppression through pandemic contact restrictions M Koltai, F Krauer, D Hodgson, E van Leeuwen, ... Epidemics 40, 100614, 2022 | 34 | 2022 |
| Estimates for quality of life loss due to Respiratory Syncytial Virus D Hodgson, KE Atkins, M Baguelin, J Panovska‐Griffiths, D Thorrington, ... Influenza and other respiratory viruses 14 (1), 19-27, 2020 | 31 | 2020 |
| Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination D Hodgson, N Wilkins, E van Leeuwen, CH Watson, J Crofts, S Flasche, ... The Lancet Regional Health–Europe 38, 2024 | 29 | 2024 |
| Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study X Li, D Hodgson, J Flaig, A Kieffer, WL Herring, H Beyhaghi, L Willem, ... Value in health 26 (4), 508-518, 2023 | 29 | 2023 |
| Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales D Hodgson, M Koltai, F Krauer, S Flasche, M Jit, KE Atkins Vaccine 40 (49), 7151-7157, 2022 | 27 | 2022 |
| Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust H Colton, D Hodgson, H Hornsby, R Brown, J Mckenzie, KL Bradley, ... Wellcome Open Research 6, 220, 2022 | 23 | 2022 |
| Modelling multi-scale cell–tissue interaction of tissue-engineered muscle constructs R Torii, RI Velliou, D Hodgson, V Mudera Journal of Tissue Engineering 9, 2041731418787141, 2018 | 18 | 2018 |
| A systematic review and meta-analysis of the effects of non-pharmacological interventions on quality of life in adults with multiple sclerosis V Gitman, K Moss, D Hodgson European journal of medical research 28 (1), 294, 2023 | 13 | 2023 |
| Estimating RSV seasonality from pandemic disruptions: a modelling study F Krauer, TE Fjelde, M Koltai, D Hodgson, M Treskova-Schwarzbach, ... medRxiv, 2022.06. 18.22276591, 2022 | 4 | 2022 |
| Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants TW Russell, H Townsley, S Abbott, J Hellewell, EJ Carr, L Chapman, ... medRxiv, 2023 | 3 | 2023 |
| Modelling muscles in vitro: a finite element analysis study D Hodgson, V Mudera, R Torii Master thesis, University College London Depository, London, 2015 | 3 | 2015 |
| Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19 Y Liu, S Sánchez-Ovando, L Carolan, L Dowson, A Khvorov, J Hadiprodjo, ... medRxiv, 2023 | 2 | 2023 |
| Vaccination of Older Adults Against Respiratory Syncytial Virus: The Final Pieces of the Puzzle KE Atkins, D Hodgson Clinical infectious diseases 77 (3), 490-491, 2023 | | 2023 |
| EE622 Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Prevention Interventions in Children: A Model Comparison Study XX Li, D Hodgson, J Flaig, A Kieffer, W Herring, H Beyhaghi, L Willem, ... Value in Health 25 (12), S178, 2022 | | 2022 |
| Evaluating the impact of Respiratory Syncytial Virus immunisation strategies on antibiotic use and drug resistant bacterial infections in England KE Atkins, D Hodgson, M Jit, NG Davies Wellcome Open Research 7 (286), 286, 2022 | | 2022 |
| Estimating RSV seasonality from pandemic disruptions: a modelling study (preprint) F Krauer, TE Fjelde, M Koltai, D Hodgson, M Treskova-Schwarzbach, ... | | 2022 |
Katherine E. AtkinsProfessor (LSHTM) & Reader/Chancellor's Fellow (University of Edinburgh)Email verificata su ed.ac.uk
